First launch for Daiichi Sankyo's long-acting inhaled flu drug
This article was originally published in Scrip
Daiichi Sankyo has launched in Japan the long-acting inhaled neuraminidase inhibitor, Inavir (laninamivir octanoate hydrate), for the treatment of A and B type flu infections.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.